40
Participants
Start Date
December 11, 2024
Primary Completion Date
December 31, 2027
Study Completion Date
December 31, 2029
Phased Variant Enrichment and Detection Sequencing (PhasED-seq)
PhasED-seq designed to detect minimal residual disease (MRD) as indicated by the presence of circulating tumor DNA (ctDNA) evidenced by an aggregate signal of phased variants (PVs) in the plasma of patients diagnosed with large B-cell lymphoma (LBCL) following first-line therapy.
Standard of Care Treatment
Standard of Care Treatment for cycles 1-6
De-escalated Treatment
Standard of Care Treatment for cycles 1-4 and de-escalated treatment for cycles 5 and 6
RECRUITING
Columbia University, New York
Collaborators (1)
National Cancer Institute (NCI)
NIH
Conquer Cancer Foundation
OTHER
Foresight Diagnostics
UNKNOWN
Hua-Jay J Cherng, MD
OTHER